Molecular Partners (MOLN) Competitors $3.70 -0.01 (-0.38%) Closing price 10/3/2025 03:37 PM EasternExtended Trading$3.70 0.00 (-0.03%) As of 10/3/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MOLN vs. OPT, AQST, CMPS, IVA, CRVS, ORGO, ZVRA, CTMX, ESPR, and CMPXShould you be buying Molecular Partners stock or one of its competitors? The main competitors of Molecular Partners include Opthea (OPT), Aquestive Therapeutics (AQST), COMPASS Pathways (CMPS), Inventiva (IVA), Corvus Pharmaceuticals (CRVS), Organogenesis (ORGO), Zevra Therapeutics (ZVRA), CytomX Therapeutics (CTMX), Esperion Therapeutics (ESPR), and Compass Therapeutics (CMPX). These companies are all part of the "pharmaceutical products" industry. Molecular Partners vs. Its Competitors Opthea Aquestive Therapeutics COMPASS Pathways Inventiva Corvus Pharmaceuticals Organogenesis Zevra Therapeutics CytomX Therapeutics Esperion Therapeutics Compass Therapeutics Opthea (NASDAQ:OPT) and Molecular Partners (NASDAQ:MOLN) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, earnings, risk and media sentiment. Does the media favor OPT or MOLN? In the previous week, Opthea had 2 more articles in the media than Molecular Partners. MarketBeat recorded 2 mentions for Opthea and 0 mentions for Molecular Partners. Opthea's average media sentiment score of 1.11 beat Molecular Partners' score of 0.00 indicating that Opthea is being referred to more favorably in the media. Company Overall Sentiment Opthea Positive Molecular Partners Neutral Do analysts recommend OPT or MOLN? Opthea currently has a consensus price target of $1.33, suggesting a potential downside of 60.90%. Molecular Partners has a consensus price target of $8.00, suggesting a potential upside of 116.45%. Given Molecular Partners' stronger consensus rating and higher probable upside, analysts plainly believe Molecular Partners is more favorable than Opthea.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Opthea 2 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.00Molecular Partners 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50 Which has more risk and volatility, OPT or MOLN? Opthea has a beta of 1.17, suggesting that its stock price is 17% more volatile than the S&P 500. Comparatively, Molecular Partners has a beta of 1.09, suggesting that its stock price is 9% more volatile than the S&P 500. Is OPT or MOLN more profitable? Opthea's return on equity of 0.00% beat Molecular Partners' return on equity.Company Net Margins Return on Equity Return on Assets OptheaN/A N/A N/A Molecular Partners N/A -50.66%-45.13% Do institutionals & insiders have more ownership in OPT or MOLN? 56.0% of Opthea shares are owned by institutional investors. Comparatively, 26.6% of Molecular Partners shares are owned by institutional investors. 3.2% of Opthea shares are owned by insiders. Comparatively, 5.9% of Molecular Partners shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has preferable valuation & earnings, OPT or MOLN? Molecular Partners has higher revenue and earnings than Opthea. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOpthea$30K19,437.00-$162.79MN/AN/AMolecular Partners$5.65M26.41-$61.39M-$2.08-1.78 SummaryOpthea beats Molecular Partners on 7 of the 13 factors compared between the two stocks. Get Molecular Partners News Delivered to You Automatically Sign up to receive the latest news and ratings for MOLN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MOLN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MOLN vs. The Competition Export to ExcelMetricMolecular PartnersMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$149.77M$3.33B$6.09B$10.57BDividend YieldN/A2.27%5.68%4.70%P/E Ratio-1.7822.1477.9126.71Price / Sales26.41406.35576.77177.88Price / CashN/A47.2037.7961.25Price / Book0.939.9312.546.56Net Income-$61.39M-$52.80M$3.31B$277.70M7 Day Performance-4.00%5.22%4.25%2.41%1 Month Performance3.53%13.01%7.81%9.30%1 Year Performance-26.37%25.18%71.37%31.22% Molecular Partners Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MOLNMolecular Partners1.2511 of 5 stars$3.70-0.4%$8.00+116.5%-19.3%$149.77M$5.65M-1.78180OPTOpthea0.4349 of 5 stars$3.41+7.2%$1.33-60.9%-23.5%$583.10M$30K0.008News CoverageGap UpHigh Trading VolumeAQSTAquestive Therapeutics2.47 of 5 stars$5.59-1.1%$10.29+84.0%+23.9%$563.44M$44.13M-7.99160CMPSCOMPASS Pathways3.052 of 5 stars$5.73-2.4%$16.29+184.2%+9.2%$563.17MN/A-3.11120IVAInventiva3.3564 of 5 stars$5.79-1.4%$15.57+168.9%+257.8%$561.54M$9.95M0.00100Analyst ForecastCRVSCorvus Pharmaceuticals1.7595 of 5 stars$7.37+1.2%$13.00+76.4%+36.7%$542.46MN/A-7.3030News CoverageHigh Trading VolumeORGOOrganogenesis3.8544 of 5 stars$4.22-0.9%$7.33+73.8%+50.0%$540.41M$482.04M-30.14950ZVRAZevra Therapeutics2.8948 of 5 stars$9.51-0.3%$24.00+152.4%+35.8%$535.53M$23.61M-45.2920Analyst DowngradeCTMXCytomX Therapeutics4.1629 of 5 stars$3.19-1.2%$5.42+69.8%+192.0%$532.67M$141.10M5.70170Gap UpESPREsperion Therapeutics3.8507 of 5 stars$2.65+0.4%$7.00+164.2%+68.4%$532.28M$332.31M-5.41200News CoverageGap UpCMPXCompass Therapeutics2.3651 of 5 stars$3.50-8.4%$13.88+296.4%+94.7%$528.24M$850K-7.7820Positive NewsHigh Trading Volume Related Companies and Tools Related Companies Opthea Competitors Aquestive Therapeutics Competitors COMPASS Pathways Competitors Inventiva Competitors Corvus Pharmaceuticals Competitors Organogenesis Competitors Zevra Therapeutics Competitors CytomX Therapeutics Competitors Esperion Therapeutics Competitors Compass Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MOLN) was last updated on 10/4/2025 by MarketBeat.com Staff From Our PartnersNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredElon’s Out 🚫. Trump’s DOGE Payouts Keep Flowing (Up to $32K a Year)DOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...Angel Publishing | SponsoredU.S. Government Sparking Crypto RallySecond Chances Don't Come Often in Crypto My "Crypto Bull Run Millionaire Blueprint" reveals everything - w...Crypto 101 Media | SponsoredThe Fed Just Got Kneecapped — Here’s What Happens NextDonald Trump has done it again! This time, with the signing of the highly controversial new law S.1582 — he...Banyan Hill Publishing | SponsoredTilson: “I’m watching HOOD”A strange chasm is coming to Wall Street... It's already creating millionaires and billionaires at the fast...Stansberry Research | SponsoredThese financial titans stride the earth, invisibleUBS says millionaire ranks have surged 5-fold — but many of these new millionaires aren’t tech moguls or Wall ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Molecular Partners AG Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Molecular Partners With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MOLN Stock Alerts